会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Co-microprecipitation of nanoparticulate pharmaceutical agents with
crystal growth modifiers
    • 纳米颗粒药剂与晶体生长改性剂的共沉淀
    • US5665331A
    • 1997-09-09
    • US370998
    • 1995-01-10
    • Pranab BagchiRaymond P. ScaringeH. William Bosch
    • Pranab BagchiRaymond P. ScaringeH. William Bosch
    • A61K9/14A61K49/04
    • B82Y5/00A61K49/0485A61K9/145Y10S977/745Y10S977/881Y10S977/915Y10S977/927Y10S977/928
    • This invention describes the coprecipitation of nanoparticulate pharmaceutical agent dispersion via a process that comprises the dissolution of the said pharmaceutical agent in combination with a crystal growth modifier (CGM) in an alkaline solution and then neutralizing the said solution with an acid in the presence of suitable surface-modifying surface-active agent or agents to form a fine particle dispersion of the said pharmaceutical agent, followed by steps of diafiltration clean-up of the dispersion and then concentration of it to a desired level. This process of dispersion preparation leads to microcrystalline particles of Z-average diameters smaller than 400 nm as measured by photon correlation spectroscopy. Various modification of precipitation schemes are described, many of which are suitable for large-scale manufacture of these agent dispersions. It has been discovered that coprecipitation with CGM leads to smaller particle size compared to a case where precipitation is carried out using the pharmaceutical agent alone. Thus, this dispersion of instant invention is expected to have greater bioavailability. The CGM compound is a compound that has at least about 75% of its chemical structure identical to that of the pharmaceutical agent.
    • 本发明描述了纳米颗粒药剂分散体的共沉淀,该方法包括在碱性溶液中将所述药剂与晶体生长调节剂(CGM)组合溶解,然后在适当的存在下用酸中和所述溶液 表面改性表面活性剂或试剂以形成所述药剂的细颗粒分散体,然后将分散体进行渗滤清洗,然后将其浓缩至期望水平。 这种分散制备过程导致通过光子相关光谱测量的Z平均直径小于400nm的微晶颗粒。 描述了各种改性的沉淀方案,其中许多适用于这些试剂分散体的大规模制造。 已经发现,与仅使用药剂进行沉淀的情况相比,CGM的共沉淀导致较小的粒度。 因此,本发明的这种分散体预期具有更大的生物利用度。 CGM化合物是其化学结构的至少约75%与药剂相同的化合物。